---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-060093"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:40:32.140834+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 60 Degrees Pharma enrolls first patient in tafenoquine babesiosis study at Tufts Medical Center

## Summary
- IRB approval received for open-label expanded access study of tafenoquine in immunocompromised patients with persistent babesiosis.
- Goal is to confirm 80% cure rate (30-100% CI) from Yale April 2024 case series published in Clinical Infectious Diseases.
- Three-part program: acute hospitalized (enrolling), expanded access (announced), and chronic babesiosis (planned, gated by NC State study).
- Company plans to file NDA for supplemental babesiosis indication by Q2 2026.
- U.S. accessible market estimate: 38,000 acute immunosuppressed patients and at least 375,000 chronic babesiosis patients through 2035.

## SEC filing metadata
- accession: 0001213900-24-060093
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390024060093/0001213900-24-060093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390024060093/ea0209161-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-060093
- JSON: https://secwatch.observer/filing/0001213900-24-060093.json
- Plain text: https://secwatch.observer/filing/0001213900-24-060093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.